BChE
Butyrylcholinesterase (BChE, EC 3.1.1.8) is a cholinesterase family enzyme that hydrolyzes a broad range of choline esters and other ester-containing substrates, contributing to cholinergic regulation as well as xenobiotic detoxification processes[1][2]. BChE is widely distributed in human tissues and plasma, where it participates in cholinergic transmission, ester metabolism, and the neutralization of toxic compounds including organophosphates and carbamates[1]. Mechanistically, BChE functions as a hydrolytic enzyme that can buffer acetylcholine metabolism when acetylcholinesterase (AChE) activity is reduced, thereby influencing cholinergic homeostasis[2]. In disease contexts, increasing evidence links BChE to neurodegenerative disorders, particularly Alzheimer’s disease (AD), where BChE activity and expression become more prominent during disease progression and are associated with late-stage cholinergic dysfunction[3][4]. Experimental studies therefore consider BChE an important therapeutic target and biomarker candidate for AD-related research[3][4]. Compared with the closely related isoform AChE, which primarily terminates synaptic acetylcholine signaling, BChE exhibits broader substrate specificity, distinct tissue distribution, and a stronger role in drug metabolism, detoxification, and non-neuronal physiological processes[1][2]. For experimental applications, selective BChE inhibitors are widely used to investigate cholinergic mechanisms and have been developed as pharmacological tools for evaluating therapeutic strategies in neurodegenerative disease models, with high selectivity over AChE considered a key design objective[3][4].
References:
- [1]. Hajimohammadi S, et al. New views on physiological functions and regulation of butyrylcholinesterase and potential therapeutic interventions. Front Mol Biosci. 2025 Jun 19;12:1625318. [Content Brief]
- [2]. Jovičić SM. Enzyme ChE, et al. Enzyme ChE, cholinergic therapy and molecular docking: Significant considerations and future perspectives. Int J Immunopathol Pharmacol. 2024 Jan-Dec;38:3946320241289013. [Content Brief]
- [3]. Brus B, et al. Discovery, biological evaluation, and crystal structure of a novel nanomolar selective butyrylcholinesterase inhibitor. J Med Chem. 2014 Oct 9;57(19):8167-79. [Content Brief]
- [4]. Zhou Y, et al. Discovery of Selective Butyrylcholinesterase (BChE) Inhibitors through a Combination of Computational Studies and Biological Evaluations. Molecules. 2019 Nov 20;24(23):4217. [Content Brief]
All Product Categories
-
BChE Related Products (222)
Related Products (222)
-
AChE/BChE-IN-19
0 ImagesCat. No.: HY-161508CAS No.: 3036136-22-5AChE/BChE-IN-19 (Compound 12) is a nicotinic hydrazide derivative. AChE/BChE-IN-19 is a inhibitor of AChE (IC50 = 21.45 nM) and BChE (IC50 =18.42 nM). AChE/BChE-IN-19 can be used in Alzheimer's disease research.
-
Isograndifoliol
0 ImagesCat. No.: HY-N10781CAS No.: 1445475-53-5Isograndifoliol is a selective inhibitor of butyrylcholinesterase (BChE) with an IC50 value of 0.9 μM. And Isograndifoliol moderately inhibits acetylcholinesterase (AChE) with an IC50 value of 342.9 μM. Isograndifoliol also has vasorelaxant effect and anti-tumor effect. Isograndifoliol can be used for research against dementia caused by neurodegenerative diseases.
-
hBChE-IN-1
0 ImagesCat. No.: HY-149273CAS No.: 1776948-12-9hBChE-IN-1 (compound 4), a quinolizidinyl derivative, is a potent hBChE inhibitor (IC50=7 nM) and highly selective over hAChE. hBChE-IN-1 shows inhibitory activity against tau and Aβ40 protein aggregation, with IC50 values of 20 and 4.3 μM, respectively. hBChE-IN-1 can be used for Alzheimer's disease research.
-
AChE/BChE-IN-34
0 ImagesCat. No.: HY-181167AChE/BChE-IN-34 is an acetylcholinesterase (AChE) and butyrylcholinesterase (BChE) inhibitor with IC50s of 5.97 μM and 4.57 μM, respectively. AChE/BChE-IN-34 functions as an antioxidant, oxidative stress inhibitor, reduces MDA levels, and elevates SOD and catalase in hippocampal tissue. AChE/BChE-IN-34 acts as a cognitive function enhancer, improves learning and memory in a Scopolamine (HY-N0296)-induced animal model. AChE/BChE-IN-34 is non-toxic in neuroblastoma cells across a specified concentration range. AChE/BChE-IN-34 can be used for the research of Alzheimer's disease.
-
BuChE-IN-5
0 ImagesCat. No.: HY-150585CAS No.: 2402753-39-1BuChE-IN-5 (compound 25b) is a potent BuChE inhibitor with an IC50 value of 1.94 μM. BuChE-IN-5 efficiently inhibits aggregation Aβ and tau protein in Escherichia coli. BuChE-IN-5 also has free radical scavenging capacity and antioxidant activity. BuChE-IN-5 can be used for researching Alzheimer’s disease.
-
MAO-B-IN-48
0 ImagesCat. No.: HY-175523MAO-B-IN-48 is a selective MAO-B inhibitor (IC50 = 0.09 μM, Ki = 0.02 μM). MAO-B-IN-48 exhibits inhibitory activity against hBChE (IC50 = 1.10 μM, Ki = 0.43 μM) and AChE (IC50 = 0.56 μM, Ki = 0.14 μM). MAO-B-IN-48 suppresses self-induced aggregation of toxic β-amyloid peptides and exerts antioxidant activity, including DPPH radical scavenging, CUPRAC copper ion reduction, and superoxide anion scavenging. MAO-B-IN-48 can be used for the study of Alzheimer's disease (AD).
-
N-Nornuciferine hydrochloride
0 ImagesCat. No.: HY-N2129ACAS No.: 58546-00-2N-Nornuciferine hydrochloride is an orally active, blood-brain barrier-permeable CYP2D6 inhibitor, with an IC50 of 3.76 μM and a Ki of 2.34 μM against human CYP2D6. N-Nornuciferine hydrochloride also acts as a BChE inhibitor, showing an IC50 of 5.6 μM in mice. N-Nornuciferine hydrochloride can be used in the research of neurological-related diseases.
-
hAChE/hBACE-1-IN-2
0 ImagesCat. No.: HY-149288hAChE/hBACE-1-IN-2 is a potent, orally active, blood-brain barrier transboundary triple inhibitor of hAChE, hBChE, and HACE-1 with IC50s of 0.113 μM, 1.48 μM and 0.38 μM, respectively. hAChE/hBACE-1-IN-2 has antioxidant activity. hAChE/hBACE-1-IN-2 also inhibits Aβ11-42 aggregation. hAChE/hBACE-1-IN-2 can be used to study Alzheimer's disease.
-
AChE/BChE-IN-36
0 ImagesCat. No.: HY-182290AChE/BChE-IN-36 is a dual acetylcholinesterase (AChE) and butyrylcholinesterase (BChE) inhibitor with blood-brain barrier permeability. AChE/BChE-IN-36 mediates blood-brain barrier transport through specific interactions with choline transporters. AChE/BChE-IN-36 can be used for the research of Alzheimer's disease.
-
Vescalagin
0 ImagesCat. No.: HY-N19401CAS No.: 36001-47-5Vescalagin is a hexahydroxyphenol. Vescalagin is isolable from Camu-camu (Myrciaria dubia) and immature wax apple fruits. Vescalagin exhibits inhibitory activity against a variety of enzymes, with a Ki value of 5.87 nM against AChE, 3.89 nM against BChE, 11.75 nM against hCA I, 16.23 nM against hCA II, and 16.08 nM against α-glucosidase. Vescalagin inhibits hCA I, hCA II and α-glucosidase in a non-competitive manner. Vescalagin downregulates JNK/p38 MAPK to protect pancreatic β-cells and improve insulin secretion in methylglyoxal-treated rats. Vescalagin reduces hyperglycemia and hypertriglyceridemia in rats fed a high-fructose diet. Vescalagin possesses anti-inflammatory and antioxidant properties.
-
Thunberginol C
0 ImagesCat. No.: HY-N1151CAS No.: 147517-06-4Thunberginol C is an orally active, selective, and non-competitive inhibitor of AChE and BChE, with IC50 values of 41.96 and 42.36 μM, respectively. Thunberginol C exerts cytoprotective, pro-collagen type I restorative, MMP-1 inhibitory, hyaluronic acid restorative, anti-photoaging effects in skin cells. Thunberginol C exerts neuroprotective, anxiolytic, TNF-α inhibitory, neuroinflammation inhibitory, and oxidative stress inhibitory effects. Thunberginol C can be used for the research of Alzheimer’s disease, UVB-induced skin photoaging, allergic reactions, oral bacterial infections, and stress-induced anxiety.
-
BChE-IN-53
0 ImagesCat. No.: HY-W1058380CAS No.: 25870-73-9BChE-IN-53 is a butyrylcholinesterase (BChE) inhibitor with an IC50 value of 119.0 μM and is inactive against α-glucosidase. BChE-IN-53 can be used for the research of alzheimer's disease, type 2 diabetes mellitus.
-
7-Methoxytacrine
0 ImagesCat. No.: HY-W049312CAS No.: 5778-80-3Synonyms: 7-MEOTA7-Methoxytacrine (7-MEOTA) is an inhibitor of human acetylcholinesterase (hAChE) with an IC50 value of 10 μM, and can be used for the research of Alzheimer's disease (AD).
-
ZINC12613047
0 ImagesCat. No.: HY-113905CAS No.: 1069521-64-7ZINC12613047 is a selective BChE inhibitor with an IC50 of 0.021 μM against huBChE. ZINC12613047 can be used for the research of Alzheimer's disease.
-
Demeton-S
0 ImagesCat. No.: HY-W332450CAS No.: 126-75-0Demeton-S is an organophosphate insecticide. Demeton-S inhibits butyrylcholinesterase and acetylcholinesterase activity.
-
Trichlorfon ethyl
0 ImagesTrichlorfon ethyl is an analog of Trichlorfon (HY-B1220), as well as an inhibitor of Butyrylcholinesterase and Bacillus subtilis Esterase. Trichlorfon ethyl acts as a prenatal brain growth inhibitor, causing mild reductions in total brain weight, medulla oblongata weight and tectum weight in newborn guinea pigs, without affecting cerebellar weight. Trichlorfon ethyl does not induce severe prenatal brain hypoplasia in guinea pig offspring. Trichlorfon ethyl can be used in studies related to brain hypoplasia.
